Please assess the completion status of the following clinical trial:

Trial Title: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.~* Presence of measurable disease per RECIST v1.1.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* Laboratory and medical history parameters not within the Protocol-defined range.~* Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.~* Previous radiotherapy within 2 weeks of starting study therapy.~* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Has not recovered to ≤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.~* Receipt of a live vaccine within 30 days of planned start of study therapy.~* Active infection requiring systemic therapy.~* Subjects who have any active or inactive autoimmune disease or syndrome.~* Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group A (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
- Treatment Group B (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
- Treatment Group C (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + carboplatin and paclitaxel
- Treatment Group D (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
- Treatment Group E (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + cyclophosphamide
- Treatment Group F (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
- Treatment Group G (Type: EXPERIMENTAL): Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil

Based on this trial design, predict the completion outcome and termination type (if applicable).